Analysts' Actions: P CI HUM LPX RDC

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Cigna ( CI) upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $56 price target. New analyst also placed the company on the US Focus List. Company can continue to grow the business and return capital to shareholders. $56 price target.

Cepheid ( CPHD) rated new Hold at Cantor. Valuation call, based on a $40 price target.

Equifax ( EFX) rated new Hold at Deutsche Bank. Valuation call, based on a $47 price target.

Humana ( HUM) downgraded at Credit Suisse from Outperform to Neutral, Credit Suisse said. $74 price target. New analyst has a $74 price target.

Louisiana-Pacific ( LPX) upgraded at BofA/Merrill from Underperform to Buy, Bank of America/Merrill Lynch said. Valuation call, based on a $16 price target.

Louisiana-Pacific downgraded at Deutsche. LPX was downgraded from Buy to Hold, Deutsche Bank said. Valuation call, based on a $12 price target.

Pandora ( P) upgraded at Canaccord from Hold to Buy, Canaccord Genuity said. Visibility is improving. $16 price target.

Rowan ( RDC) rated new Outperform at Credit Suisse. RDC was initiated with an Outperform rating, Credit Suisse said. $50 price target. Company was also placed on the Focus List. Company trades at a discount to its peers.

Vertex Pharmaceuticals ( VRTX) rated new Buy at ThinkEquity. $64 price target. Kalydeco should drive near-term growth.

STOCK COMMENTS / EPS CHANGES

Brown Forman ( BF.B) numbers raised at UBS. Shares of BF.b now seen reaching $72, UBS said. Estimates also increased on positive outlook. Buy rating.

HJ Heinz ( HNZ) numbers reduced at Credit Suisse. HNZ estimates were cut through 2015, Credit Suisse said. Company is seeing lower operating earnings. Neutral rating and new $57 price target.

Joy Global ( JOY) numbers lowered at Jefferies. Shares of JOY now seen reaching $50, Jefferies said. Estimates also lowered on poor revenue outlook. Hold rating.

Pandora ( P) estimates, target raised at Credit Suisse. Shares of P now seen reaching $13, according to Credit Suisse. Estimates also increased, as the company is realizing higher operating leverage. Neutral rating.

UnitedHealth ( UNH) cut from US Focus List at Credit Suisse. New analyst has a $62 price target. Outperform rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.